EnliTISA

FOUNDED IN OCTOBER 2018 BY PROFESSOR BENGT SAMUELSSON, A NOBEL PRICE LAUREATE, PROFESSOR JAN-CHRISTER JANSON, DR. GU MING AND HER TEAM. ENLITISA IS A CHINESE-SWEDISH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR INFLAMMATORY AND FIBROTIC DISEASES WITH HIGH UNMET MEDICAL NEED

Improving lives for patients with serious inflammatory and fibrotic diseases

EnliTISA

R & D Innovation

Original research R & D pipeline TISA 818 Montelukast sodium

Our team

Anders Kärnell

Anders Kärnell

Anders Kärnell

Jiang Taotao (Cathy)

Jiang Taotao (Cathy)

Jiang Taotao (Cathy)

The world's leading original innovative 
drug enterprise for inflammation and injury

Welcome to join us

News

The world's leading original innovative drug enterprise for inflammation and injury

READ MORE

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. was recognized on the "Top 50 Innovation & Entrepreneurship Enterprises" list of the China Innovation & Entrepreneurship Competition.

EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was honored at the ‌Award Ceremony of the 13th China Innovation & Entrepreneurship Competition Finals‌ on December 7, 2024, organized by the Torch High Technology Industry Development Center, Ministry of Industry and Information Technology. The company was recognized on two prestigious lists: • ‌"Best Enterprise in Local Competitions of the 13th China Innovation & Entrepreneurship Competition"‌ • ‌"Top 50 Innovation & Entrepreneurship Enterprises of the 13th China Innovation & Entrepreneurship Competition"‌‌. The event highlighted outstanding enterprises from 37 regional competitions nationwide, with 1,000 companies advancing to the national stage‌. EnliTISA’s inclusion reflects its exemplary performance in technological innovation and industrial impact during the competition series.

The company was honored with the ‌"2024 Pudong Innovation & Entrepreneurship Star"‌ award.

The 2024 Pudong Innovation & Entrepreneurship Conference, organized by the Shanghai Pudong New Area Economic and Science & Technology Commission, was officially inaugurated at the New Area People’s Government on November 29, 2024.

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. was selected for the "2024 Shanghai Top 50 Most Investment-Promising Startups" list.

The 17th Bund Finance · Shanghai International Equity Investment Forum was held in Huangpu on December 10, 2024‌. With the theme "Invest in Shanghai, Innovate for the Future," the forum gathered top investors, industry experts, entrepreneurs, and innovators to explore collaborative opportunities‌. EnliTISA (Shanghai) Pharmaceutical Co., Ltd. was selected for the "2024 Shanghai Top 50 Most Investment-Promising Startups" list announced at the event‌.

EnliTISA(Shanghai) Pharmaceutical Co., Ltd. won the Second Prize in the Bio-medicine National Competition of the China Innovation & Entrepreneurship Grand Prix.

From November 19 to 21, 2024, the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix, organized by the Torch Center of the Ministry of Industry and Information Technology, was successfully concluded. During the event, numerous outstanding enterprises emerged in the bio-medicine field. Among them, EnliTISA (Shanghai) Pharmaceutical Co., Ltd. stood out with exceptional performance and was awarded the "Second Prize in the Bio-medicine National Competition of the 13th China Innovation & Entrepreneurship Grand Prix."

The first CTA and clinical study of EnliTISA Pharmaceuticals TISA-818 for treating idiopathic pulmonary fibrosis has been approved by the MPA

On November 27, 2023, EnliTISA Pharmaceuticals TISA-818, a Class I innovative drug for the treatment of idiopathic pulmonary fibrosis, was approved by the MPA.